Literature DB >> 32859995

GSK3β inhibition restores cortical gamma oscillation and cognitive behavior in a mouse model of NMDA receptor hypofunction relevant to schizophrenia.

Kazuhito Nakao1,2, Mahendra Singh1, Kiran Sapkota1, Bailey C Hagler1, Robert N Hunter3, Chander Raman4, John J Hablitz5, Kazu Nakazawa6,7.   

Abstract

Cortical gamma oscillations are believed to be involved in mental processes which are disturbed in schizophrenia. For example, the magnitudes of sensory-evoked oscillations, as measured by auditory steady-state responses (ASSRs) at 40 Hz, are robustly diminished, whereas the baseline gamma power is enhanced in schizophrenia. Such dual gamma oscillation abnormalities are also present in a mouse model of N-methyl-D-aspartate receptor hypofunction (Ppp1r2cre/Grin1 knockout mice). However, it is unclear whether the abnormal gamma oscillations are associated with dysfunction in schizophrenia. We found that glycogen synthase kinase-3 (GSK3) is overactivated in corticolimbic parvalbumin-positive GABAergic interneurons in Grin1 mutant mice. Here we addressed whether GSK3β inhibition reverses both abnormal gamma oscillations and behavioral deficits with high correlation by pharmacological and genetic approach. We demonstrated that the paralog selective-GSK3β inhibitor, but not GSK3α inhibitor, normalizes the diminished ASSRs, excessive baseline gamma power, and deficits in spatial working memory and prepulse inhibition (PPI) of acoustic startle in Grin1 mutant mice. Cell-type specific GSK3B knockdown, but not GSK3A knockdown, also reversed abnormal gamma oscillations and behavioral deficits. Moreover, GSK3B knockdown, but not GSK3A knockdown, reverses the mutants' in vivo spike synchrony deficits. Finally, ex vivo patch-clamp recording from pairs of neighboring cortical pyramidal neurons showed a reduction of synchronous spontaneous inhibitory-postsynaptic-current events in mutants, which was reversed by GSK3β inhibition genetically and pharmacologically. Together, GSK3β inhibition in corticolimbic interneurons ameliorates the deficits in spatial working memory and PPI, presumably by restoration of synchronous GABA release, synchronous spike firing, and evoked-gamma power increase with lowered baseline power.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32859995      PMCID: PMC7784891          DOI: 10.1038/s41386-020-00819-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  39 in total

1.  Neural synchrony indexes disordered perception and cognition in schizophrenia.

Authors:  Kevin M Spencer; Paul G Nestor; Ruth Perlmutter; Margaret A Niznikiewicz; Meredith C Klump; Melissa Frumin; Martha E Shenton; Robert W McCarley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

2.  Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients.

Authors:  Gregory A Light; Jung Lung Hsu; Ming H Hsieh; Katrin Meyer-Gomes; Joyce Sprock; Neal R Swerdlow; David L Braff
Journal:  Biol Psychiatry       Date:  2006-08-07       Impact factor: 13.382

3.  NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia.

Authors:  John A Saunders; Michael J Gandal; Steve J Siegel
Journal:  Neurobiol Dis       Date:  2012-01-09       Impact factor: 5.996

4.  Gamma frequency-range abnormalities to auditory stimulation in schizophrenia.

Authors:  J S Kwon; B F O'Donnell; G V Wallenstein; R W Greene; Y Hirayasu; P G Nestor; M E Hasselmo; G F Potts; M E Shenton; R W McCarley
Journal:  Arch Gen Psychiatry       Date:  1999-11

Review 5.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

6.  Frontal areas contribute to reduced global coordination of resting-state gamma activities in drug-naïve patients with schizophrenia.

Authors:  Mitsuru Kikuchi; Takanori Hashimoto; Tatsuya Nagasawa; Tetsu Hirosawa; Yoshio Minabe; Masafumi Yoshimura; Werner Strik; Thomas Dierks; Thomas Koenig
Journal:  Schizophr Res       Date:  2011-06-22       Impact factor: 4.939

Review 7.  Abnormal neural oscillations and synchrony in schizophrenia.

Authors:  Peter J Uhlhaas; Wolf Singer
Journal:  Nat Rev Neurosci       Date:  2010-02       Impact factor: 34.870

8.  Increased Resting-State Gamma-Band Connectivity in First-Episode Schizophrenia.

Authors:  Christina Andreou; Guido Nolte; Gregor Leicht; Nenad Polomac; Ileana L Hanganu-Opatz; Martin Lambert; Andreas K Engel; Christoph Mulert
Journal:  Schizophr Bull       Date:  2014-08-28       Impact factor: 9.306

9.  N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex.

Authors:  Didier Pinault
Journal:  Biol Psychiatry       Date:  2007-11-26       Impact factor: 13.382

10.  Opposite effects of ketamine and deep brain stimulation on rat thalamocortical information processing.

Authors:  Sofya P Kulikova; Elena A Tolmacheva; Paul Anderson; Julien Gaudias; Brendan E Adams; Thomas Zheng; Didier Pinault
Journal:  Eur J Neurosci       Date:  2012-08-29       Impact factor: 3.386

View more
  5 in total

1.  Pharmacological intervention in young adolescents rescues synaptic physiology and behavioural deficits in Syngap1+/- mice.

Authors:  Vijaya Verma; M J Vijay Kumar; Kavita Sharma; Sridhar Rajaram; Ravi Muddashetty; Ravi Manjithaya; Thomas Behnisch; James P Clement
Journal:  Exp Brain Res       Date:  2021-11-05       Impact factor: 1.972

2.  5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction.

Authors:  Kazuhito Nakao; Mahendra Singh; Kiran Sapkota; Andrew Fitzgerald; John J Hablitz; Kazu Nakazawa
Journal:  Transl Psychiatry       Date:  2022-04-22       Impact factor: 7.989

Review 3.  Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.

Authors:  Ido Rippin; Hagit Eldar-Finkelman
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

4.  The Reduction of Tau Hyperphosphorylation by Cornel Iridoid Glycosides Is Mediated by Their Influence on Calpain Activity.

Authors:  Kaiwen Guo; Cuicui Yang; Lan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-20       Impact factor: 2.629

Review 5.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.